Sweden
· Delayed Price · Currency is SEK Vicore Pharma Holding AB Statistics
Total Valuation
Vicore Pharma Holding AB has a market cap or net worth of SEK 1.84 billion. The enterprise value is 1.37 billion.
| Market Cap | 1.84B |
| Enterprise Value | 1.37B |
Important Dates
The next estimated earnings date is Tuesday, November 5, 2024.
| Earnings Date | Nov 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Vicore Pharma Holding AB has 111.73 million shares outstanding. The number of shares has decreased by -0.85% in one year.
| Shares Outstanding | 111.73M |
| Shares Change (YoY) | -0.85% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 6.26% |
| Owned by Institutions (%) | 33.73% |
| Float | 71.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 17.54 |
| PB Ratio | 4.23 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.86 |
| EV / Sales | 13.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.98
| Current Ratio | 11.98 |
| Quick Ratio | 11.72 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -54.28% and return on invested capital (ROIC) is -37.78%.
| Return on Equity (ROE) | -54.28% |
| Return on Assets (ROA) | -34.01% |
| Return on Capital (ROIC) | -37.78% |
| Revenue Per Employee | 3.72M |
| Profits Per Employee | -7.15M |
| Employee Count | 24 |
| Asset Turnover | 0.25 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +10.77% in the last 52 weeks. The beta is 0.71, so Vicore Pharma Holding AB's price volatility has been lower than the market average.
| Beta (5Y) | 0.71 |
| 52-Week Price Change | +10.77% |
| 50-Day Moving Average | 18.25 |
| 200-Day Moving Average | 16.70 |
| Relative Strength Index (RSI) | 40.04 |
| Average Volume (20 Days) | 139,385 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Vicore Pharma Holding AB had revenue of SEK 104.24 million and -200.06 million in losses. Loss per share was -1.80.
| Revenue | 104.24M |
| Gross Profit | 104.24M |
| Operating Income | -222.80M |
| Pretax Income | -200.45M |
| Net Income | -200.06M |
| EBITDA | -219.44M |
| EBIT | -222.80M |
| Loss Per Share | -1.80 |
Balance Sheet
| Cash & Cash Equivalents | 466.44M |
| Total Debt | n/a |
| Net Cash | 466.44M |
| Net Cash Per Share | 4.17 |
| Equity (Book Value) | 434.98M |
| Book Value Per Share | 3.89 |
| Working Capital | 438.24M |
Cash Flow
| Operating Cash Flow | -129.30M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 100.00%, with operating and profit margins of -213.73% and -191.92%.
| Gross Margin | 100.00% |
| Operating Margin | -213.73% |
| Pretax Margin | -192.29% |
| Profit Margin | -191.92% |
| EBITDA Margin | -210.51% |
| EBIT Margin | -213.73% |
| FCF Margin | n/a |
Dividends & Yields
Vicore Pharma Holding AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.85% |
| Shareholder Yield | 0.85% |
| Earnings Yield | -10.94% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |